Clinical Trial Update: Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Participants (VICTOR-E1) (MK-7690-020/P03672) [Phase 2]

View source ↗

Summary

Phase 2 trial update for Vicriviroc (SCH 417690) in combination with optimized ART in experienced HIV patients; study completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Vicriviroc (MK-7690)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV Infections | Phase 2 | Status: COMPLETED | Results posted: 2021-06-08